Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 62 entries
Sorted by: Best Match Show Resources per page
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.

Gynecologic oncology research and practice

Cobb LP, Gaillard S, Wang Y, Shih IeM, Secord AA.
PMID: 27231561
Gynecol Oncol Res Pract. 2015 May 12;2:1. doi: 10.1186/s40661-015-0008-z. eCollection 2015.

Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classification systems for ovarian cancer have proposed two primary histologic groups that encompass the standard histologic...

Cite
Cobb LP, Gaillard S, Wang Y, et al. Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract. 2015;2:1doi: 10.1186/s40661-015-0008-z.
Cobb, L. P., Gaillard, S., Wang, Y., Shih, I. e. M., & Secord, A. A. (2015). Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecologic oncology research and practice, 21. https://doi.org/10.1186/s40661-015-0008-z
Cobb, Lauren Patterson, et al. "Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms." Gynecologic oncology research and practice vol. 2 (2015): 1. doi: https://doi.org/10.1186/s40661-015-0008-z
Cobb LP, Gaillard S, Wang Y, Shih IeM, Secord AA. Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract. 2015 May 12;2:1. doi: 10.1186/s40661-015-0008-z. eCollection 2015. PMID: 27231561; PMCID: PMC4880836.
Copy Download .nbib Format: NLM
Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field.

Gynecologic oncology research and practice

Coleman RL, Herzog TJ, Monk BJ, Dooner P.
PMID: 27231554
Gynecol Oncol Res Pract. 2014 Sep 30;1:1. doi: 10.1186/2053-6844-1-1. eCollection 2014.

No abstract available.

Cite
Coleman RL, Herzog TJ, Monk BJ, et al. Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field. Gynecol Oncol Res Pract. 2014;1:1doi: 10.1186/2053-6844-1-1.
Coleman, R. L., Herzog, T. J., Monk, B. J., & Dooner, P. (2014). Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field. Gynecologic oncology research and practice, 11. https://doi.org/10.1186/2053-6844-1-1
Coleman, Robert L, et al. "Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field." Gynecologic oncology research and practice vol. 1 (2014): 1. doi: https://doi.org/10.1186/2053-6844-1-1
Coleman RL, Herzog TJ, Monk BJ, Dooner P. Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field. Gynecol Oncol Res Pract. 2014 Sep 30;1:1. doi: 10.1186/2053-6844-1-1. eCollection 2014. PMID: 27231554; PMCID: PMC4878069.
Copy Download .nbib Format: NLM
Impact of cervical cancer on quality of life: beyond the short term (Results from a single institution): Quality of life in long-term cervical cancer survivors: results from a single institution.

Gynecologic oncology research and practice

Khalil J, Bellefqih S, Sahli N, Afif M, Elkacemi H, Elmajjaoui S, Kebdani T, Benjaafar N.
PMID: 27231567
Gynecol Oncol Res Pract. 2015 Sep 19;2:7. doi: 10.1186/s40661-015-0011-4. eCollection 2015.

BACKGROUND: Cervical cancer (CC) is one of the most widespread gynecological malignancies in women worldwide. Treatment strategies and screening modalities have largely evolved these past years resulting in an improvement of survival. However, treatment modalities are associated with long...

Cite
Khalil J, Bellefqih S, Sahli N, et al. Impact of cervical cancer on quality of life: beyond the short term (Results from a single institution): Quality of life in long-term cervical cancer survivors: results from a single institution. Gynecol Oncol Res Pract. 2015;2:7doi: 10.1186/s40661-015-0011-4.
Khalil, J., Bellefqih, S., Sahli, N., Afif, M., Elkacemi, H., Elmajjaoui, S., Kebdani, T., & Benjaafar, N. (2015). Impact of cervical cancer on quality of life: beyond the short term (Results from a single institution): Quality of life in long-term cervical cancer survivors: results from a single institution. Gynecologic oncology research and practice, 27. https://doi.org/10.1186/s40661-015-0011-4
Khalil, J, et al. "Impact of cervical cancer on quality of life: beyond the short term (Results from a single institution): Quality of life in long-term cervical cancer survivors: results from a single institution." Gynecologic oncology research and practice vol. 2 (2015): 7. doi: https://doi.org/10.1186/s40661-015-0011-4
Khalil J, Bellefqih S, Sahli N, Afif M, Elkacemi H, Elmajjaoui S, Kebdani T, Benjaafar N. Impact of cervical cancer on quality of life: beyond the short term (Results from a single institution): Quality of life in long-term cervical cancer survivors: results from a single institution. Gynecol Oncol Res Pract. 2015 Sep 19;2:7. doi: 10.1186/s40661-015-0011-4. eCollection 2015. PMID: 27231567; PMCID: PMC4880873.
Copy Download .nbib Format: NLM
Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.

Gynecologic oncology research and practice

Rodriguez-Freixinos V, Mackay HJ.
PMID: 27231568
Gynecol Oncol Res Pract. 2015 Sep 21;2:8. doi: 10.1186/s40661-015-0015-0. eCollection 2015.

Despite the introduction of screening and, latterly, vaccination programs in the developed world, globally cervical cancer remains a significant health problem. For those diagnosed with advanced or recurrent disease even within resource rich communities, prognosis remains poor with an...

Cite
Rodriguez-Freixinos V, Mackay HJ. Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future. Gynecol Oncol Res Pract. 2015;2:8doi: 10.1186/s40661-015-0015-0.
Rodriguez-Freixinos, V., & Mackay, H. J. (2015). Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future. Gynecologic oncology research and practice, 28. https://doi.org/10.1186/s40661-015-0015-0
Rodriguez-Freixinos, Victor, and Mackay, Helen J. "Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future." Gynecologic oncology research and practice vol. 2 (2015): 8. doi: https://doi.org/10.1186/s40661-015-0015-0
Rodriguez-Freixinos V, Mackay HJ. Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future. Gynecol Oncol Res Pract. 2015 Sep 21;2:8. doi: 10.1186/s40661-015-0015-0. eCollection 2015. PMID: 27231568; PMCID: PMC4881045.
Copy Download .nbib Format: NLM
EZH2 inhibition in .

Gynecologic oncology research and practice

Alldredge JK, Eskander RN.
PMID: 29093822
Gynecol Oncol Res Pract. 2017 Oct 31;4:17. doi: 10.1186/s40661-017-0052-y. eCollection 2017.

Clear cell carcinoma and endometrioid adenocarcinoma are histologic subtypes of ovarian and uterine cancer that demonstrate unique clinical behavior but share common underlying genomic aberrations and oncogenic pathways.

Cite
Alldredge JK, Eskander RN. EZH2 inhibition in . Gynecol Oncol Res Pract. 2017;4:17doi: 10.1186/s40661-017-0052-y.
Alldredge, J. K., & Eskander, R. N. (2017). EZH2 inhibition in . Gynecologic oncology research and practice, 417. https://doi.org/10.1186/s40661-017-0052-y
Alldredge, Jill K, and Eskander, Ramez N. "EZH2 inhibition in ." Gynecologic oncology research and practice vol. 4 (2017): 17. doi: https://doi.org/10.1186/s40661-017-0052-y
Alldredge JK, Eskander RN. EZH2 inhibition in . Gynecol Oncol Res Pract. 2017 Oct 31;4:17. doi: 10.1186/s40661-017-0052-y. eCollection 2017. PMID: 29093822; PMCID: PMC5663065.
Copy Download .nbib Format: NLM
Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.

Gynecologic oncology research and practice

Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J.
PMID: 29318022
Gynecol Oncol Res Pract. 2018 Jan 05;5:1. doi: 10.1186/s40661-017-0058-5. eCollection 2018.

Combretastatin A4-phosphate (CA4P) is a vascular-disrupting agent (VDA) in clinical development for the treatment of ovarian and other cancers. In contrast to antiangiogenic agents, such as bevacizumab, which suppress the development of new tumor vasculature, VDAs target established tumor...

Cite
Grisham R, Ky B, Tewari KS, et al. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract. 2018;5:1doi: 10.1186/s40661-017-0058-5.
Grisham, R., Ky, B., Tewari, K. S., Chaplin, D. J., & Walker, J. (2018). Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecologic oncology research and practice, 51. https://doi.org/10.1186/s40661-017-0058-5
Grisham, Rachel, et al. "Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management." Gynecologic oncology research and practice vol. 5 (2018): 1. doi: https://doi.org/10.1186/s40661-017-0058-5
Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract. 2018 Jan 05;5:1. doi: 10.1186/s40661-017-0058-5. eCollection 2018. PMID: 29318022; PMCID: PMC5756341.
Copy Download .nbib Format: NLM
Improving attendance to genetic counselling services for gynaecological oncology patients.

Gynecologic oncology research and practice

Pokharel HP, Hacker NF, Andrews L.
PMID: 29344385
Gynecol Oncol Res Pract. 2018 Jan 10;5:2. doi: 10.1186/s40661-018-0059-z. eCollection 2018.

BACKGROUND: Gynaecological cancers may be the sentinel malignancy in women who carry a mutation in BRCA1 or 2, a mis-match repair gene causing Lynch Syndrome or other genes. Despite published guidelines for referral to a genetics service, a substantial...

Cite
Pokharel HP, Hacker NF, Andrews L. Improving attendance to genetic counselling services for gynaecological oncology patients. Gynecol Oncol Res Pract. 2018;5:2doi: 10.1186/s40661-018-0059-z.
Pokharel, H. P., Hacker, N. F., & Andrews, L. (2018). Improving attendance to genetic counselling services for gynaecological oncology patients. Gynecologic oncology research and practice, 52. https://doi.org/10.1186/s40661-018-0059-z
Pokharel, Hanoon P, et al. "Improving attendance to genetic counselling services for gynaecological oncology patients." Gynecologic oncology research and practice vol. 5 (2018): 2. doi: https://doi.org/10.1186/s40661-018-0059-z
Pokharel HP, Hacker NF, Andrews L. Improving attendance to genetic counselling services for gynaecological oncology patients. Gynecol Oncol Res Pract. 2018 Jan 10;5:2. doi: 10.1186/s40661-018-0059-z. eCollection 2018. PMID: 29344385; PMCID: PMC5763520.
Copy Download .nbib Format: NLM
Extra-uterine low grade endometrioid stromal sarcoma arising from ovarian endometriosis: a case report and review of the literature.

Gynecologic oncology research and practice

Efared B, Sidibé IS, Erregad F, Hammas N, Chbani L, El Fatemi H.
PMID: 30723546
Gynecol Oncol Res Pract. 2019 Jan 29;6:2. doi: 10.1186/s40661-019-0067-7. eCollection 2019.

BACKGROUND: Endometrial stromal sarcoma (ESS) is a rare neoplasm accounting for only 0.2% of female genital tract tumors. The primary extra-uterine location of ESS is an extremely uncommon occurrence.CASE PRESENTATION: We present a case of a 64-year-old woman presenting...

Cite
Efared B, Sidibé IS, Erregad F, et al. Extra-uterine low grade endometrioid stromal sarcoma arising from ovarian endometriosis: a case report and review of the literature. Gynecol Oncol Res Pract. 2019;6:2doi: 10.1186/s40661-019-0067-7.
Efared, B., Sidibé, I. S., Erregad, F., Hammas, N., Chbani, L., & El Fatemi, H. (2019). Extra-uterine low grade endometrioid stromal sarcoma arising from ovarian endometriosis: a case report and review of the literature. Gynecologic oncology research and practice, 62. https://doi.org/10.1186/s40661-019-0067-7
Efared, Boubacar, et al. "Extra-uterine low grade endometrioid stromal sarcoma arising from ovarian endometriosis: a case report and review of the literature." Gynecologic oncology research and practice vol. 6 (2019): 2. doi: https://doi.org/10.1186/s40661-019-0067-7
Efared B, Sidibé IS, Erregad F, Hammas N, Chbani L, El Fatemi H. Extra-uterine low grade endometrioid stromal sarcoma arising from ovarian endometriosis: a case report and review of the literature. Gynecol Oncol Res Pract. 2019 Jan 29;6:2. doi: 10.1186/s40661-019-0067-7. eCollection 2019. PMID: 30723546; PMCID: PMC6350347.
Copy Download .nbib Format: NLM
A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer.

Gynecologic oncology research and practice

Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, Smith JA.
PMID: 29158911
Gynecol Oncol Res Pract. 2017 Nov 14;4:16. doi: 10.1186/s40661-017-0053-x. eCollection 2017.

BACKGROUND: While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/carboplatin and gemcitabine/cisplatin have a similar ORR in separate clinical trials, the...

Cite
Le TN, Harvey RE, Kim CK, et al. A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer. Gynecol Oncol Res Pract. 2017;4:16doi: 10.1186/s40661-017-0053-x.
Le, T. N., Harvey, R. E., Kim, C. K., Brown, J., Coleman, R. L., & Smith, J. A. (2017). A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer. Gynecologic oncology research and practice, 416. https://doi.org/10.1186/s40661-017-0053-x
Le, Tran N, et al. "A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer." Gynecologic oncology research and practice vol. 4 (2017): 16. doi: https://doi.org/10.1186/s40661-017-0053-x
Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, Smith JA. A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer. Gynecol Oncol Res Pract. 2017 Nov 14;4:16. doi: 10.1186/s40661-017-0053-x. eCollection 2017. PMID: 29158911; PMCID: PMC5684736.
Copy Download .nbib Format: NLM
Fertility preservation in women with cervical, endometrial or ovarian cancers.

Gynecologic oncology research and practice

Feichtinger M, Rodriguez-Wallberg KA.
PMID: 27468354
Gynecol Oncol Res Pract. 2016 Jul 27;3:8. doi: 10.1186/s40661-016-0029-2. eCollection 2016.

BACKGROUND: Although cancer in general affects an aged population, a significant number of women develop cancer at childbearing age. Long-term survival rates after gynecological cancer, especially in young patients are increasing and all quality-of-life aspects, including preservation of fertility...

Cite
Feichtinger M, Rodriguez-Wallberg KA. Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract. 2016;3:8doi: 10.1186/s40661-016-0029-2.
Feichtinger, M., & Rodriguez-Wallberg, K. A. (2016). Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecologic oncology research and practice, 38. https://doi.org/10.1186/s40661-016-0029-2
Feichtinger, Michael, and Rodriguez-Wallberg, Kenny A. "Fertility preservation in women with cervical, endometrial or ovarian cancers." Gynecologic oncology research and practice vol. 3 (2016): 8. doi: https://doi.org/10.1186/s40661-016-0029-2
Feichtinger M, Rodriguez-Wallberg KA. Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract. 2016 Jul 27;3:8. doi: 10.1186/s40661-016-0029-2. eCollection 2016. PMID: 27468354; PMCID: PMC4962474.
Copy Download .nbib Format: NLM
Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya.

Gynecologic oncology research and practice

Degu A, Njogu P, Weru I, Karimi P.
PMID: 29075505
Gynecol Oncol Res Pract. 2017 Oct 18;4:15. doi: 10.1186/s40661-017-0054-9. eCollection 2017.

BACKGROUND: Although cervical cancer is preventable, it is still the second leading cause of cancer deaths among women in the world. Further, it is estimated that around 5-10% of hospital admissions are due to drug related problems (DRPs), of...

Cite
Degu A, Njogu P, Weru I, et al. Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya. Gynecol Oncol Res Pract. 2017;4:15doi: 10.1186/s40661-017-0054-9.
Degu, A., Njogu, P., Weru, I., & Karimi, P. (2017). Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya. Gynecologic oncology research and practice, 415. https://doi.org/10.1186/s40661-017-0054-9
Degu, Amsalu, et al. "Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya." Gynecologic oncology research and practice vol. 4 (2017): 15. doi: https://doi.org/10.1186/s40661-017-0054-9
Degu A, Njogu P, Weru I, Karimi P. Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya. Gynecol Oncol Res Pract. 2017 Oct 18;4:15. doi: 10.1186/s40661-017-0054-9. eCollection 2017. PMID: 29075505; PMCID: PMC5648473.
Copy Download .nbib Format: NLM
Disparities in the surgical staging of high-grade endometrial cancer in the United States.

Gynecologic oncology research and practice

Foote JR, Gaillard S, Broadwater G, Sosa JA, Davidson B, Adam MA, Secord AA, Jones MB, Chino J, Havrilesky LJ.
PMID: 28116108
Gynecol Oncol Res Pract. 2017 Jan 19;4:1. doi: 10.1186/s40661-016-0036-3. eCollection 2017.

BACKGROUND: The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer. Our goal was to examine surgical staging patterns...

Cite
Foote JR, Gaillard S, Broadwater G, et al. Disparities in the surgical staging of high-grade endometrial cancer in the United States. Gynecol Oncol Res Pract. 2017;4:1doi: 10.1186/s40661-016-0036-3.
Foote, J. R., Gaillard, S., Broadwater, G., Sosa, J. A., Davidson, B., Adam, M. A., Secord, A. A., Jones, M. B., Chino, J., & Havrilesky, L. J. (2017). Disparities in the surgical staging of high-grade endometrial cancer in the United States. Gynecologic oncology research and practice, 41. https://doi.org/10.1186/s40661-016-0036-3
Foote, Jonathan R, et al. "Disparities in the surgical staging of high-grade endometrial cancer in the United States." Gynecologic oncology research and practice vol. 4 (2017): 1. doi: https://doi.org/10.1186/s40661-016-0036-3
Foote JR, Gaillard S, Broadwater G, Sosa JA, Davidson B, Adam MA, Secord AA, Jones MB, Chino J, Havrilesky LJ. Disparities in the surgical staging of high-grade endometrial cancer in the United States. Gynecol Oncol Res Pract. 2017 Jan 19;4:1. doi: 10.1186/s40661-016-0036-3. eCollection 2017. PMID: 28116108; PMCID: PMC5247803.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 62 entries